THE SCIENCE
Semaglutide is a GLP-1 receptor agonist that has been studied extensively in relation to glucose regulation, appetite, body weight, and metabolic health. The sections below provide scientific background on its receptor activity, metabolic signaling, and clinical research.
MOLECULAR DESIGN
Semaglutide is a modified peptide analogue of human GLP-1 designed to interact with the GLP-1 receptor while having a substantially longer duration of action than native GLP-1.
GLP-1 RECEPTOR ACTIVITY
Semaglutide activates the GLP-1 receptor. Research has examined how GLP-1 receptor signaling influences glucose regulation, insulin secretion, appetite, and energy balance.
METABOLIC SIGNALING
GLP-1 receptor signaling influences processes involved in glucose regulation, insulin secretion, gastric emptying, appetite, and energy balance. Clinical research on semaglutide has examined changes in body weight and a range of metabolic measures.
BODY WEIGHT & METABOLIC EFFECTS
- Semaglutide has been studied extensively for its effects on body weight and metabolic measures. Clinical trials have evaluated changes in body weight, waist circumference, glycemic measures, blood pressure, lipid measures, and other cardiometabolic endpoints.
CLINICAL RESEARCH
The STEP clinical trial program has evaluated semaglutide in adults with obesity or overweight, with studies examining changes in body weight and related metabolic outcomes over different treatment periods.
PHASE 3 RESEARCH
In the 68-week STEP 1 randomized, double-blind, placebo-controlled trial, adults with obesity or overweight and a weight-related condition, without diabetes, received semaglutide or placebo alongside lifestyle intervention. Mean body-weight change at week 68 was −14.9% with semaglutide compared with −2.4% with placebo. The study also reported improvements in waist circumference and several cardiometabolic